JP2013523629A - ペプチドの経皮投与方法 - Google Patents

ペプチドの経皮投与方法 Download PDF

Info

Publication number
JP2013523629A
JP2013523629A JP2013500647A JP2013500647A JP2013523629A JP 2013523629 A JP2013523629 A JP 2013523629A JP 2013500647 A JP2013500647 A JP 2013500647A JP 2013500647 A JP2013500647 A JP 2013500647A JP 2013523629 A JP2013523629 A JP 2013523629A
Authority
JP
Japan
Prior art keywords
cys
lys
seq
trp
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2013500647A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523629A5 (enExample
Inventor
パトリック・バーナード・ディージー
トーマス・キーラン・ロフマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Manufacturing Ireland Ltd
Original Assignee
Ipsen Manufacturing Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Manufacturing Ireland Ltd filed Critical Ipsen Manufacturing Ireland Ltd
Publication of JP2013523629A publication Critical patent/JP2013523629A/ja
Publication of JP2013523629A5 publication Critical patent/JP2013523629A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013500647A 2010-03-25 2011-03-23 ペプチドの経皮投与方法 Ceased JP2013523629A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IE20100174A IE20100174A1 (en) 2010-03-25 2010-03-25 Transdermal administration of peptides
IE2010/0174 2010-03-25
PCT/IE2011/000019 WO2011117851A1 (en) 2010-03-25 2011-03-23 Transdermal administration of peptides

Publications (2)

Publication Number Publication Date
JP2013523629A true JP2013523629A (ja) 2013-06-17
JP2013523629A5 JP2013523629A5 (enExample) 2014-05-08

Family

ID=44210069

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013500647A Ceased JP2013523629A (ja) 2010-03-25 2011-03-23 ペプチドの経皮投与方法

Country Status (12)

Country Link
US (1) US20130085105A1 (enExample)
EP (1) EP2550005A1 (enExample)
JP (1) JP2013523629A (enExample)
KR (1) KR20130062275A (enExample)
CN (1) CN102883735A (enExample)
AU (1) AU2011231173A1 (enExample)
BR (1) BR112012022377A2 (enExample)
CA (1) CA2792470A1 (enExample)
IE (1) IE20100174A1 (enExample)
MX (1) MX2012010343A (enExample)
RU (1) RU2012145278A (enExample)
WO (1) WO2011117851A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022508676A (ja) * 2018-10-11 2022-01-19 コロシアム・コンビナトリアル・ケミストリー・センター・フォー・テクノロジー・ソチエタ・ア・レスポンサビリタ・リミタータ・イン・フォルマ・アッブレヴィアータ・チ４ティ・ソチエタ・ア・レスポンサビリタ・リミタータ 皮膚の老化および光老化の処置および予防に有効なペプチド

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102665401A (zh) 2009-11-16 2012-09-12 益普生制药股份有限公司 黑皮质素受体配体的药物组合物
WO2011115871A1 (en) * 2010-03-15 2011-09-22 Ipsen Pharma S.A.S. Pharmaceutical compositions of growth hormone secretagogue receptor ligands
SI2568806T1 (sl) 2010-05-12 2016-09-30 Radius Health, Inc. Režimi zdravljenja
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
TWI662967B (zh) * 2013-03-25 2019-06-21 日商志瑞亞新藥工業股份有限公司 食後期之胃運動亢進劑
PT3122426T (pt) 2014-03-28 2023-02-28 Univ Duke Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio
US10266579B2 (en) 2014-09-14 2019-04-23 Tel Hashomer Medical Research Infrastructure And Services Ltd. Synthetic somatostatin receptor ligands
EP3288383A4 (en) 2015-04-29 2019-01-23 Radius Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
KR20230137362A (ko) 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
HRP20220619T1 (hr) 2016-06-22 2023-02-03 Ellipses Pharma Ltd Postupci za liječenje ar+ raka dojke
ES2981967T3 (es) 2017-01-05 2024-10-14 Radius Pharmaceuticals Inc Formas polimórficas de RAD1901-2HCl
KR101786914B1 (ko) * 2017-01-31 2017-11-15 주식회사 삼양사 피부 리프팅 또는 탄력 개선을 위한 점착성 탄력 밴드
CN107226840A (zh) * 2017-05-04 2017-10-03 西安交通大学 一种细胞穿膜肽透皮吸收促进剂及其制备方法和应用
CA3076751A1 (en) * 2017-09-26 2019-04-04 Aquestive Therapeutics, Inc. Delivery pharmaceutical compositions including permeation enhancers
WO2019236603A1 (en) * 2018-06-08 2019-12-12 Saint Louis University Methods and compositions for treating decreased cognitive ability
JP7473486B2 (ja) 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形形態
JOP20210218A1 (ar) 2019-02-12 2023-01-30 Radius Pharmaceuticals Inc عمليات ومركبات
DE102020130492A1 (de) * 2020-11-18 2022-05-19 Lts Lohmann Therapie-Systeme Ag. Temperiersystem für eine Diffusionszelle, Diffusionszelle, Diffusionszellensystem, sowie Verfahren zur Temperierung in einer Diffusionszelle
WO2023281447A1 (en) * 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175329A1 (en) * 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
JP2005518335A (ja) * 2001-06-25 2005-06-23 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス 下垂体腺腫の増殖を阻害する医薬組成物およびそれを使用する方法
WO2008143958A1 (en) * 2007-05-18 2008-11-27 The Brigham And Women's Hospital, Inc. Use of somatostatin analogs in myocardial perfusion imaging
JP2009532384A (ja) * 2006-03-30 2009-09-10 パラティン・テクノロジーズ・インコーポレーテッド 環状ナトリウム利尿ペプチド構築物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954975A (en) * 1972-02-17 1976-05-04 Ciba-Geigy Corporation Salts of ACTH-peptides and processes for their manufacture
IL79134A (en) * 1985-07-29 1991-06-10 American Cyanamid Co Continuous release peptide implants for parenteral administration
JPH08505367A (ja) * 1992-10-16 1996-06-11 スミスクライン・ビーチャム・コーポレイション 医薬用エマルジョン組成物
US6316414B1 (en) * 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
WO2006040447A1 (fr) * 2004-10-07 2006-04-20 L'oreal Procédé de traitement cosmétique des fibres kératiniques et utilisation d'un inhibiteur de transglutaminase
US20060216242A1 (en) * 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
JP5231412B2 (ja) * 2006-07-11 2013-07-10 キューピーエス リミテッド ライアビリティ カンパニー ペプチドを持続的放出により送達するための薬理組成物
GB0705264D0 (en) * 2007-03-20 2007-04-25 Pliva Istrazivanje I Razvoj D Gel forming compounds
WO2009100222A1 (en) * 2008-02-08 2009-08-13 Qps Llc Non-polymeric compositions for controlled drug delivery

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005518335A (ja) * 2001-06-25 2005-06-23 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス 下垂体腺腫の増殖を阻害する医薬組成物およびそれを使用する方法
US20030175329A1 (en) * 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
JP2009532384A (ja) * 2006-03-30 2009-09-10 パラティン・テクノロジーズ・インコーポレーテッド 環状ナトリウム利尿ペプチド構築物
WO2008143958A1 (en) * 2007-05-18 2008-11-27 The Brigham And Women's Hospital, Inc. Use of somatostatin analogs in myocardial perfusion imaging

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6015016227; Ｉｎｔ．　Ｊ．　Ｐｈａｒｍ．，　２０００，　Ｖｏｌ．　２０３，　Ｎｏ．　１-２，　ｐｐ．　１９３-２０２ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022508676A (ja) * 2018-10-11 2022-01-19 コロシアム・コンビナトリアル・ケミストリー・センター・フォー・テクノロジー・ソチエタ・ア・レスポンサビリタ・リミタータ・イン・フォルマ・アッブレヴィアータ・チ４ティ・ソチエタ・ア・レスポンサビリタ・リミタータ 皮膚の老化および光老化の処置および予防に有効なペプチド

Also Published As

Publication number Publication date
BR112012022377A2 (pt) 2017-01-10
CN102883735A (zh) 2013-01-16
US20130085105A1 (en) 2013-04-04
KR20130062275A (ko) 2013-06-12
IE20100174A1 (en) 2012-02-29
WO2011117851A1 (en) 2011-09-29
MX2012010343A (es) 2013-01-29
EP2550005A1 (en) 2013-01-30
CA2792470A1 (en) 2011-09-29
AU2011231173A1 (en) 2012-10-18
RU2012145278A (ru) 2014-04-27

Similar Documents

Publication Publication Date Title
JP2013523629A (ja) ペプチドの経皮投与方法
US8536120B2 (en) Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
Bednarek et al. Structure− function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a
KR102351313B1 (ko) Gip/glp1 공효능제 화합물
Ghigo et al. Growth hormone-releasing peptides
KR101662044B1 (ko) 인슐린 민감성을 치료하기 위한 멜라노코르틴의 용도
TWI331922B (en) Growth hormone releasing peptides
US8580918B2 (en) Peptidic GLP-2 agonists
US8729227B2 (en) Compounds for control of appetite
JP2023071869A (ja) グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト
AU2011268256B8 (en) Growth hormone secretatogue receptor antagonists and uses thereof
CA3174635A1 (en) Peptides as selective gip receptor agonists
WO2020077129A1 (en) Human amylin analog polypeptides and methods of use
EP3630806B1 (en) Long-acting gip peptide analogues
JP2024536727A (ja) 強力で選択的なｇｉｐ受容体アゴニストとしての新規のペプチド
CN100368014C (zh) 通过给予生长激素释放化合物或其拮抗剂来治疗肿瘤
JP2013501053A (ja) 脂質異常症を治療するためのメラノコルチンの使用
WO2017200944A1 (en) Glucagon receptor/glp-1 receptor selective analog polypeptides and methods of use thereof
KR20210052381A (ko) 항비만 효능을 갖는 펩타이드(펩타이드 15) 및 이의 용도
CN115226391A (zh) 胰高血糖素和glp-1受体的钉合三唑共激动剂
CA2470235C (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
HK1180959A (en) Transdermal administration of peptides
US8846616B1 (en) Alpha-melanocyte stimulating hormone as topical anti-inflammatory agent for the treatment of allergic contact dermatitis and eczema
US20210002231A1 (en) Hybrid mu opioid receptor and neuropeptide ff receptor binding molecules, their methods of preparation and applications in therapeutic treatment
Hargrove et al. Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140318

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20150427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150428

AA92 Notification that decision to refuse application was cancelled

Free format text: JAPANESE INTERMEDIATE CODE: A971092

Effective date: 20150519